Johnson & Johnson Eyes Double-Digit Growth Horizon: Is the Healthcare Giant's Stock Now a Value Play?
After years of steady but modest expansion, Johnson & Johnson projects a significant acceleration in revenue, driven by a bold ambition to dominate the global oncology market. With shares trading at a premium, analysts debate if the stock's future growth potential justifies its current price.